2023 ASH | Hengsai Biotechnology to go to the international academic stage and present the latest research results of hematological oncology

65thAmerican Society of Hematology (ASH) Annual MeetingHeld on December 9-12, 2023 in San Diego, USA, as the largest, most numerous and most influential annual meeting in the field of international hematology, this ASH Congress gathered 35,000 experts and scholars from 109 countries and regions around the world to present their latest results, exchange the latest experience in research, and discuss the latest trends in the development of hematology. 

Experts and scholars attending this international academic event, in the intense four-day period, in the form of conference exchanges and venue boards, achieved the purpose of exchanging academics, communicating information, enhancing understanding, passing on friendship and strengthening cooperation, and pointed out the direction for future research and development of hematology.

Hengsai Biotechnologya biotechnology company dedicated to immunotherapy.Founder Dr. Huining LiuAfter returning to China, he led an excellent team to continue his basic immunology research at Harvard Medical School and translate the results. Initial Research ResultsKSD-101 in patients with EBV-associated hematologic neoplasms: results of an ongoing phase I clinical study.Selected for this event and attracting attention .

The study showed thatAutologous Dendritic Cell (DCC) Vaccine, which has a favorable safety profile for the treatment of EB (Epstein-Barr) virus-associated hematologic neoplasms, is effective in inducing an immune response and has achieved encouraging clinical efficacy.

EBV (Epstein-Barr virus) is a common virus that is closely associated with the development and progression of many hematologic tumors. The treatment of EBV-associated hematologic tumors is still a clinical challenge.

KSD-101 is a new product developed by Hengsai Biotechnology.Novel cellular drugs targeting EBV-associated hematologic tumors, by inducing the specific immune function of dendritic cells against tumors and enhancing the body's ability to attack tumor cells, thus achieving the purpose of inhibiting tumor growth and proliferation.

Being able to present its research results on the highest international academic stage of hematology and being recognized by its peers fully reflects the scientific strength and influence of Hengsai Biologicals in the field of hematology research, and it is hoped that such cutting-edge research can make positive exploration and breakthroughs in the treatment of hematological diseases.

In this feast of academic exchanges, Hengsai Bio-team participated in several seminars and presentations related to our research direction. The experts were full of interest in our research, and discussed and exchanged with us in depth, sharing different views and experiences. This atmosphere of academic exchanges not only broadened our horizons, but also met many colleagues . It is this atmosphere that stimulates innovative thinking and promotes the rapid development of hematology research.

At the same time, the interview of Prof. Chunrui Li of the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, the PI of the clinical research of KSD-101 by Medical Pulse also let more people know the latest research results of Hengsai Biologicals, and increased the company's popularity. This interview is not only a recognition of Hengsai Bio, but also an affirmation of the results of our team's efforts.

We have benefited greatly from this international academic exchange that transcends borders, races and beliefs. The research results from different experiences and backgrounds have given us deep insights and new directions for solving some of the difficult problems that have been bothering us for a long time. More importantly, such on-site exchanges have inspired our confidence and motivation to continue our research efforts.

Under the leadership of Dr. Liu Huining, Hengsai Biotechnology, with the spirit of science and pioneering, is united in its efforts to become a first-class biotechnology company in the industry and work hard for the development of human science.

-END-